Increasing incidence of Candida parapsilosis candidemia with caspofungin usage

Graeme N Forrest1, Elizabeth Weekes, Jennifer K Johnson

  • 1Division of Infectious Diseases, Department of Medicine, University of Maryland, 20 Penn Street, Room S403B, Baltimore, MD 21201, USA. gforrest@medicine.umaryland.edu

The Journal of Infection
|December 18, 2007
PubMed
Abstract

Insights

The introduction of caspofungin correlated with increased Candida parapsilosis infections and decreased Candida tropicalis and Candida glabrata infections. This study highlights shifts in fungal epidemiology due to antifungal use.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Antimicrobial Stewardship

Background:

  • The epidemiology of Candida species causing candidemia can change over time.
  • Antifungal drug usage patterns may influence the prevalence of specific Candida species.

Purpose of the Study:

  • To investigate the impact of caspofungin introduction on the epidemiology of Candida species.
  • To analyze trends in candidemia and antifungal use over a five-year period.

Main Methods:

  • Retrospective review of 469 candidemia episodes from 2002-2006.
  • Collected data on antifungal defined daily doses.
  • Utilized regression and Pearson correlation analyses to assess relationships between antifungal use and Candida species.

Main Results:

  • A significant increase in Candida parapsilosis candidemia coincided with increased caspofungin usage.
  • A significant decline in conventional and lipid amphotericin B usage was observed.
  • Correlations found between higher caspofungin use and increased C. parapsilosis, decreased C. tropicalis, and a trend towards decreased C. glabrata.

Conclusions:

  • Increased caspofungin use is significantly correlated with a rise in C. parapsilosis candidemia.
  • A reduction in C. tropicalis candidemia was associated with caspofungin introduction.
  • A trend towards decreased C. glabrata candidemia was noted alongside increased caspofungin usage.

Related Concept Videos

Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).